Glycorex Transplantation AB (publ) continues its international expansion by enterering into a distribution agreement with OneMedik (M) SDN BHD, Malaysia.
OneMedik (M) SDN BHD specializes in the distribution of medical devices within plasmapheresis and has been operating in Malaysia since 2009. The company works closely with local healthcare providers to deliver critical medical technology across the region.
The agreement opens up a viable new market for Glycorex where 70% of kidney transplants are performed using living donors, an indication where Glycorex's technology is viewed as the "Gold Standard".
"We are very pleased to have this agreement in place with OneMedik and look forward to working with them to create better accessibility to our products in this region, both within transplantation and transfusion medicine applications," says Carl Magnus Schultz, CEO of Glycorex Transplantation.
For more information, please contact:
Carl-Magnus Schultz, CEO
Email: carl.schultz@glycorex.com, Phone: +46 46 286 52 30
Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.
The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 30 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets.
Product development and production takes place in the company's own facility in Lund, Sweden.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 8,000 transplants in over 30 countries.
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.